ALKEM2023-10-012023-12-31 ALKEM2023-10-012023-12-31 ALKEM2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member ALKEM2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member ALKEM2023-12-31 ALKEM2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ALKEM2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539523 ALKEM NOTLISTED Alkem Laboratories Limited Equity 2023-04-01 2024-03-31 2024-02-09 2024-02-01 INR Millions Third quarter 11:00:00 13:00:00 2024-02-09 2024-02-09 Not applicable Single segment The Company is exclusively engaged in pharmaceutical business 2023-10-01 2023-12-31 Unaudited Consolidated 33238700000.00 936400000.00 34175100000.00 8385400000.00 4608100000.00 51900000.00 5721500000.00 254600000.00 695600000.00 7395900000.00 27113000000.00 7062100000.00 -513100000.00 6549000000.00 1136000000.00 -629800000.00 506200000.00 0.00 6042800000.00 0.00 0.00 0.00 0.00 6042800000.00 54800000.00 6097600000.00 5949600000.00 93200000.00 6004200000.00 93400000.00 239100000.00 2 49.76 49.76 0.00 0.00 49.76 49.76 1. The above unaudited consolidated financial results of Alkem Laboratories Limited and its subsidiaries (collectively called the “Group”) were reviewed and recommended by the Audit Committee on 8 February 2024 and subsequently approved by the Board of Directors at its meeting held on 9 February 2024. The auditors have issued an unmodified report on the financial results for the quarter and nine months ended 31 December 2023. 2a During the previous year ended 31 March 2023, the Group had identified indicators of impairment with respect to one of the manufacturing units of S & B Pharma LLC, USA, a step-down subsidiary of the Holding Company located at St. Louis and consequently recognized an impairment loss of Rs 1,029.8 Million in the consolidated financial results for the year ended March 2023 and an additional impairment loss of Rs 576.6 Million in the consolidated financial results for the quarter ended 30 September 2023 under 'Exceptional items' based on indicative realizable value. During the year ended 31 March 2023, deferred tax assets pertaining to the above assets were no longer available for utilisation, and were derecognised in the consolidated financial statements amounting to Rs 1,197.2 million During the current quarter, the manufacturing unit has been sold at approximately its carrying value. 2b During the current quarter, a cyber security incident which compromised business email IDs of certain employees at one of the subsidiaries resulted in a fraudulent transfer of funds of approximately Rs 513.1 Million. The Group employed independent external agencies to investigate the incident and pursuant to this, the Group concluded that the impact of the incident did not extend beyond the above amount which is reported under 'Exceptional items'. 3. The Board of Directors at its meeting held on 9 February 2024 have declared an interim dividend of Rs 35 (Rupees Thirty five only) per equity share (1750% on the face value of Rs 2 each) for the financial year 2023-24. 4. The Group operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 97317600000.00 2226700000.00 99544300000.00 24958300000.00 12481700000.00 861800000.00 16951800000.00 855500000.00 2158700000.00 23628900000.00 81896700000.00 17647600000.00 -1089700000.00 16557900000.00 3384300000.00 -1896200000.00 1488100000.00 0.00 15069800000.00 0.00 0.00 0.00 0.00 15069800000.00 276900000.00 15346700000.00 15022100000.00 47700000.00 15305400000.00 41300000.00 239100000.00 2 125.64 125.64 0.00 0.00 125.64 125.64 Other Expenses 7395900000.00 Other Expenses 23628900000.00 Remeasurements of defined benefit plans -26400000.00 Remeasurements of defined benefit plans -95700000.00 -26400000.00 -95700000.00 -8200000.00 -31900000.00 Foreign currency translation difference of foreign operations 73000000.00 Foreign currency translation difference of foreign operations 340700000.00 73000000.00 340700000.00 0.00 0.00